What is the Access to Prescription Digital Therapeutics Act?

February 20, 2024

The Access to Prescription Digital Therapeutics Act is a U.S. Bill that aims to amend the Social Security Act and provide Medicare and Medicaid coverage and reimbursement for prescription digital therapeutics (PDTs). If the bill is passed it will help provide improved access to PDTs for patients across the U.S.

The Benefits of Co-Creation in Patient Companion Apps

February 1, 2024

There are several approaches to product development, one of which involves the intimate involvement of the end-user in the software design and the development process.

How AI Can Be Used in Patient-Facing Healthcare Apps

January 24, 2024

With AI's use becoming so widespread, there are likely going to be an increasing number of ways in which it is used in patient-facing healthcare apps. This article outlines some of the current use cases, and what we expect to see more of in the future.

The Business Case for Pharma Investing in Digital Companions

January 16, 2024

Next-generation digital patient companion apps offer evolving benefits, reshaping opportunities for the pharmaceutical industry to generate value. Key drivers justify the strategic investment in these apps to support the core business, which is the focus of this article.

Hans-Peter Frank appointed new Chair of the Alex Therapeutics Board

January 12, 2024

Hans-Peter Frank joins Alex Therapeutics as the new Chair of the Board, and brings a wealth of experience from the Pharma, Medtech and BioTech industries.

How Vicore Pharma and Alex Therapeutics partnered to build Almee™ - a digital therapy to treat anxiety for patients with pulmonary fibrosis

January 10, 2024

A successful partnership that has resulted in the co-creation and clinical validation of Almee, a digital treatment for anxiety in patients with pulmonary fibrosis.

Alex Therapeutics Reports Positive Results from the Randomized-Controlled Trial of its Digital Therapy for Anxiety

January 4, 2024

Alex Therapeutics and Vicore Pharma today announced positive results of the COMPANION study, investigating the efficacy of Almee, a 9-week digital CBT intervention accessed through a smartphone or tablet. The study met its primary endpoint, change from baseline in GAD-7 anxiety scores, with a statistically significant 2.7-point improvement compared to control.

Prescription drug-induced nausea and vomiting and how psychological interventions can help

December 13, 2023

Drug-induced nausea and vomiting is a common and debilitating side-effect of certain prescription medications which can have a significant impact on quality of life. In this article we review psychological interventions that can provide patients with effective coping strategies and support to manage these symptoms.

The barriers to medication adherence and how digital health solutions can help overcome them

November 30, 2023

Medication non-adherence is a complex and costly problem. In this article we do a deep, scientific dive into why medication non-adherence is a problem, the factors that influence medication non-adherence, and review the clinical studies examining whether mobile apps can improve medication adherence.

A Guide to Software as a Medical Device

November 29, 2023

Software as a Medical Device (SaMD) plays a crucial role in diagnostics, treatment, and overall healthcare management. In this guide to SaMD, we’ll explain everything you need to know about SaMD, including its definition, examples of SaMD, the regulatory landscape, development challenges, benefits, and future trends.

New digital CBT-related CPT codes provide better incentives for psychologists and physicians to use digital health solutions

November 6, 2023

This article summarises the recent changes in US Current Procedural Terminology (CPT) codes related to digital CBT and discusses how the US healthcare system is evolving when it comes to incorporating digital health solutions into clinical practice. This comes off the back of evidence from the AMA that physician’s attitudes towards digital health are shifting, with an increased appetite for digital tools.

What is ISO 27001 certification and why digital health technology companies should have it

October 30, 2023

In this article we break down what the ISO 27001 certification is and why it's important for digital health technology companies to have it.

A Summary of the new FDA Draft Guidance: Regulatory Considerations for Prescription Drug Use-Related Software (PDURS)

October 25, 2023

The new FDA guidance document Regulatory Considerations for Prescription Drug Use-Related Software describes how the FDA intends to apply its drug labeling authorities to software outputs that are disseminated by or on behalf of a drug sponsor for use with a prescription drug. In this article we give a high level summary of the key points from the guidance.

Leading the Way in Digital Health: Alex Therapeutics Welcomes Paul Kirchmeier as COO

September 1, 2023

Drawing from his background of successfully introducing and growing virtual care software and services, alongside managing decentralized trials, Paul enriches the capabilities of the Alex team and its partners.

Alex Therapeutics extends financing round to €4.75M with leading life science VC

March 3, 2023

Alex Therapeutics’ extends fundraising round to €4.75 million with major investment from Innovestor Life Science. Investing €1.25million, Innovestor joins impressive list top-tier life science and technology venture capital firms, including Hadean Ventures, Scale Capital, Sweet Capital (King founders), and Bonit Capital.

Alex Therapeutics & Vicore Pharma announce first patient enrolled in pivotal study for Almee™, a DTx anxiety therapy for pulmonary fibrosis patients

December 5, 2022

The pivotal study, investigating Alex Therapeutics’ and Vicore’s standalone digital therapy (DTx) treating anxiety in patients with pulmonary fibrosis (PF), has launched in the US. The randomized clinical investigation will evaluate the impact of dCBT-PF Almee™ in adult subjects with PF for 250 patients in a 9-week program.

Alex Therapeutics presents major Eila® clinical trial recruitment milestone

December 1, 2022

Alex Therapeutics, together with Pfizer, has reached the first major milestone in a clinical study of a digital therapeutic for the CBT-based treatment of tobacco dependence in Germany.

Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety

October 13, 2022

Alex Therapeutics presents positive results from the pilot phase of a clinical study for one of their digital therapies treating anxiety in patients with the rare disease IPF. The primary objective of the study was to test the functionality, user experience, and safety of the DTx, which were all found to be positive. Additionally, using GAD-7, anxiety symptoms were shown to have been reduced by an average of 4.2 points, a 49% reduction.

Alex Therapeutics and Vicore Pharma launch clinical investigation of PF DTx

April 21, 2022

Clinical study investigating Alex Therapeutics’ and Vicore’s standalone digital therapy (DTx) treating anxiety in patients with pulmonary fibrosis (PF) has launched in the US. The clinical study consists of two phases; the current pilot study designed to refine the interactive nature of the therapy session, followed by a pivotal study.

Alex Therapeutics raises €3.5M from top VC investors

April 6, 2022

Alex Therapeutics raises €3.5M in oversubscribed financing round from top tier VC investors to advance expansion in Europe and the US. This funding round will be used to accelerate Alex's growth in Europe and the US and to develop novel DTx products alongside both new and existing partners, including Pfizer.

Pfizer and Alex Therapeutics announce Strategic Commercial Partnership

January 31, 2022

The Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics and world-leading pharmaceutical company Pfizer have joined forces to provide evidence-based, clinically validated, and personalized digital therapies to patients. Together, the companies cover a broad range of expertise in the fields of medicine, marketing, clinical validation, AI, software development, and psychology. The partnership will initially focus on Germany, one of the world's largest unified healthcare markets.

Alex Therapeutics recieves Vinnova funding to develop tobacco cessation product in India

June 4, 2021

Alex Therapeutics has received approval and funding from Vinnova to develop, optimise and clinically validate an AI-based tobacco cessation treatment tailored to India. 

Alex Therapeutics partners with Pfizer Sweden in World No Tobacco Day campaign

May 31, 2021

Alex Therapeutics and the world leading pharmaceutical company Pfizer partner to combat the tobacco epidemic and help achieve a smoking-free society. Today, the 31st of May, is the World No Tobacco Day. Alex Therapeutics and Pfizer are seeking to draw attention to the continued global tobacco problem and as well as their collaboration to combat it. 

Vicore enters into collaboration with Alex Therapeutics to develop new prescription digital therapeutic for patients with IPF

May 4, 2021

Vicore Pharma, a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces the signing of an agreement with Alex Therapeutics for the development of a clinically validated digital therapeutic (DTx) built on the “Alex DTx Platform”.

Alex Therapeutics receives funding from the King founders

July 23, 2018

Last year the billionaire entrepreneurs behind King.com founded the venture fund Sweet Studio. The fund, which manages roughly 100 million SEK in capital, has now made its first investment in Alex Therapeutics. 

Improve patient outcomes with digital companions proven to change behavior.

We've simplified the process for pharma companies to launch indication-specific companion digital health solutions at scale. Reach out to learn more.

Get in touch